Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Molpeceres, C; Ramos-Medina, R; Marquez, A; Romero, P; Gomez-Fontela, M; Candorcio-Simon, R; Munoz, A; Lauzurica, S; del Monte-Millan, M; Morales, M; Munoz-Martin, D; Lopez-Tarruella, S; Massarrah, T; Martin, M.

Laser transfer for circulating tumor cell isolation in liquid biopsy

International Journal of Bioprinting. 2023; 9(4): Nº de citas: 6 [doi:10.18063/ijb.720]

Presa, M; Vicente, D; Calles, A; Salinas-Ortega, L; Naik, J; García, LF; Soto, J.

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

ClinicoEconomics and Outcomes Research. 2023; 15: 659-671 Nº de citas: 4 [doi:10.2147/CEOR.S415711]

Galera, M; Alvarez, R; Arregui, M; Paniagua, M; Alvarez, A; Crisostomo, RAG; Díazgranados, A; Gutiérrez, N; Calles, A; Agra, C.

A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin

Case Reports in Oncology. 2023; 16(1): 1542-1550 Nº de citas: 2 [doi:10.1159/000534935]

Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS.

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

EUROPEAN UROLOGY. 2023; 83(1): 15-26 Nº de citas: 66 [doi:10.1016/j.eururo.2022.08.005]

Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B.

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.

Revista Espanola de Patologia. 2023; 56(1): 32-44 [doi:10.1016/j.patol.2022.06.004]

Jimenez-Fonseca, P; Foy, V; Raby, S; Carmona-Bayonas, A; Macia-Rivas, L; Arrazubi, V; Lavin, DC; Gil, RHS; Custodio, A; Cano, JM; Montes, AF; Mirallas, O; Declara, IM; Tocino, RV; Visa, L; Limon, ML; Pimentel, P; Lago, NM; Sauri, T; Richard, MM; Mangas, M; Raga, MG; Calvo, A; Reguera, P; Granja, M; Carnicero, AM; Perez, CH; Cerda, P; Gonzalez, LG; Navalon, FG; Barcia, VP; Abad, D; Martin, MR; Weaver, J; Mansoor, W; Gallego, J.

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 2 [doi:10.1177/17588359231157641]

Perez-Fidalgo, JA; Ortega, E; Ponce, J; Redondo, A; Sevilla, I; Valverde, C; Verdum, JI; de Alava, E; Lopez, MG; Marquina, G; Sebio, A.

Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 31 [doi:10.1177/17588359231157645]

Arance, A; De La Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Marquez-Rodas, I; Spreafico, A; Atkinson, V; Costa Svedman F; Mant, A; Khattak, MA; Mihalcioiu, C; Jang, S; Cowey, CL; Smith, AD; Hawk, N; Chen, K; Diede, SJ; Krepler, C; Long, GV.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(1): 75-85 Nº de citas: 99 [doi:10.1200/JCO.22.00221]

Johnston SRD; Toi, M; O'Shaughnessy, J; Rastogi, P; Campone, M; Neven, P; Huang, CS; Huober, J; Jaliffe, GG; Cicin, I; Tolaney, SM; Goetz, MP; Rugo, HS; Senkus, E; Testa, L; Del Mastro, L; Shimizu, C; Wei, R; Shahir, A; Munoz, M; San Antonio, B; André V; Harbeck, N; Martin, M.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

LANCET ONCOLOGY. 2023; 24(1): 77-90 Nº de citas: 481 [doi:10.1016/S1470-2045(22)00694-5]

Munoz, A; Gallardo, E; Agnelli, G; Crespo, C; Forghani, M; Arumi, D; de Cabo, SF; Soto, J.

Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

JOURNAL OF MEDICAL ECONOMICS. 2022; 25(1): 840-847 Nº de citas: 11 [doi:10.1080/13696998.2022.2087998]

Escobar, Y; Margarit, C; Perez-Hernandez, C; Quintanar, T; Virizuela, JA.

Good practice recommendations to better coordinate the management of oncological pain: a Delphi survey

Scientific Reports. 2022; 12(1): 22459-22459 Nº de citas: 5 [doi:10.1038/s41598-022-26753-3]

Lemos, R; Areias-Marques, S; Ferreira, P; O'Brien, P; Beltran-Jaunsaras, ME; Ribeiro, G; Martin, M; Del Monte-Millan, M; Lopez-Tarruella, S; Massarrah, T; Luis-Ferreira, F; Frau, G; Venios, S; McManus, G; Oliveira-Maia, AJ.

A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol

BMC Psychiatry. 2022; 22(1): Nº de citas: 7 [doi:10.1186/s12888-022-04446-5]

Bofill, JS; Anton, FM; Sanchez, CAR; Calvo, EG; Melia, CH; Gil, EMC; Vidal, M; Jimenez-Rodriguez, B; Merino, LD; Janez, NM; Vazquez, RV; Salas, RD; Torres, AA; Lopez, IMA; Gregori, JG; Garcia, VQ; Rubio, EV; De la Haba-Rodriguez, J; Gonzalez-Santiago, S; Fernandez, ND; Molins, AB; De Ibarguen, BCS; Mingorance, JID; Ezquerra, MB; De Casa, S; Gimeno, A; Martin, M.

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

BREAST. 2022; 66: 77-84 Nº de citas: 5 [doi:10.1016/j.breast.2022.09.006]

Schettini, F; Venturini, S; Giuliano, M; Lambertini, M; Pinato, DJ; Onesti, CE; De Placido, P; Harbeck, N; Lueftner, D; Denys, H; Van Dam, P; Arpino, G; Zaman, K; Mustacchi, G; Gligorov, J; Awada, A; Campone, M; Wildiers, H; Gennari, A; Tjan-Heijnen, V; Bartsch, R; Cortes, J; Paris, I; Martin, M; De Placido, S; Del Mastro, L; Jerusalem, G; Curigliano, G; Prat, A; Generali, D.

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

CANCER TREATMENT REVIEWS. 2022; 111: Nº de citas: 28 [doi:10.1016/j.ctrv.2022.102468]

Argiles, G; Mulet, N; Valladares-Ayerbes, M; Vieitez, JM; Gravalos, C; Garcia-Alfonso, P; Santos, C; Tobena, M; Garcia-Paredes, B; Benavides, M; Cano, MT; Loupakis, F; Rodriguez-Garrote, M; Rivera, F; Goldberg, RM; Cremolini, C; Bennouna, J; Ciardiello, F; Tabernero, JM; Aranda, E; Tabernero, J.

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

EUROPEAN JOURNAL OF CANCER. 2022; 177: 154-163 Nº de citas: 18 [doi:10.1016/j.ejca.2022.09.037]

Valladares-Ayerbes, M; Garcia-Alfonso, P; Luengo, JM; Caceres, PPP; Trujillo, OAC; Vidal-Tocino, R; Llanos, M; Ayala, BL; Miron, MLL; Salud, A; Nogueras, LC; Garcia-Carbonero, R; Safont, MJ; Ferrer, EF; Aparicio, J; Conesa, MAV; Guillen-Ponce, C; Garcia-Teijido, P; Magan, MBM; Busquier, I; Salgado, M; Vila, AL; PERSEIDA Investigators.

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

Cancers. 2022; 14(24): Nº de citas: 6 [doi:10.3390/cancers14246075]

Taboada AGM; Lominchar PL; Martínez MF; García-Alfonso P; Martin AM; Asencio JM.

Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline".

Annals of Hepato-Biliary-Pancreatic Surgery. 2022; 26(4): 363-374 Nº de citas: 1 [doi:10.14701/ahbps.22-023]

Villanueva-Bueno C; Collado-Borrell R; Escudero-Vilaplana V; Revuelta-Herrero JL; Marzal-Alfaro MB; González-Haba E; Arranz-Arija JÁ; Osorio S; Herranz-Alonso A; Sanjurjo-Saez M.

A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.

Frontiers in Public Health. 2022; 10: 978783-978783 Nº de citas: 4 [doi:10.3389/fpubh.2022.978783]